公开(公告)号：EP3089757A1

公开(公告)日：2016-11-09

申请号：EP15701431.7

申请日：2015-01-02

申请人： AbbVie Inc. ,  AbbVie Deutschland GmbH & Co KG

发明人： MILLER, Jonathan M. ,  MORRIS, John B. ,  SEVER, Nancy E. ,  SCHMITT, Eric A. ,  GAO, Ping X. ,  SHI, Yi ,  GAO, Yi ,  LIEPOLD, Bernd ,  MOOSMANN, Anna ,  PAULI, Mirko ,  DURAK, Fatih ,  KESSLER, Thomas ,  HOELIG, Peter A. ,  ROSENBLATT, Karin ,  KOSTELAC, Drazen ,  GOKHALE, Rajeev ,  COSTELLO, Mark ,  KNABLE, Carl

IPC分类号： A61K47/32 ,  A61K47/38 ,  A61K9/24 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K31/513 ,  A61P31/14

CPC分类号： A61K31/513 ,  A61K9/209 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

摘要： The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

公开(公告)号：EP3313378A1

公开(公告)日：2018-05-02

申请号：EP16738291.0

申请日：2016-06-24

申请人： AbbVie Inc.

发明人： SEVER, Nancy ,  WESTEDT, Ulrich ,  LANDER, Ute ,  SCHNEIDER, Katrin ,  STEITZ, Benedikt ,  MUELLER, Thomas ,  REUL, Regina ,  OBERMILLER, Constanze ,  JAYASANKAR, Adivaraha ,  SIMON, Michael ,  GAO, Yi ,  HACH, Harald ,  KYEREMATENG, Samuel ,  ASMUS, Katharina ,  TONG, Ping ,  ZHU, Donghua ,  NARIS, Marius ,  GARRETT, Colleen

IPC分类号： A61K9/14 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K31/498 ,  A61P31/14

CPC分类号： A61K38/06 ,  A61K9/146 ,  A61K9/1688 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2866 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K2300/00

摘要： The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：EP2908808A1

公开(公告)日：2015-08-26

申请号：EP13789411.9

申请日：2013-10-18

申请人： Abbvie Inc.

发明人： LI, Yanxia ,  GAO, Ping ,  SHI, Yi ,  HOU, Hao ,  MACKAPLOW, Michael ,  MEADOWS, Kelley A. ,  ZHANG, Geoff G. ,  GAO, Yi

IPC分类号： A61K31/00 ,  A61K31/513 ,  A61K9/20

CPC分类号： A61K31/513 ,  A61K9/0053 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866

摘要： The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.

摘要翻译： 本公开涉及嘧啶二酮衍生物化合物的药物组合物及其制备和使用方法。 本公开还涉及增强施用于受试者的药物组合物中嘧啶二酮衍生物化合物的生物利用度的方法和减少药物组合物中嘧啶二酮衍生物化合物的量同时在受试者中实现相同生物利用度的方法。

公开(公告)号：EP2797586A1

公开(公告)日：2014-11-05

申请号：EP12809070.1

申请日：2012-12-18

申请人： AbbVie Inc.

发明人： GAO, Yi ,  ZHANG, Geoff G.Z.

IPC分类号： A61K9/16 ,  A61K31/497 ,  A61P31/14

CPC分类号： A61K45/06 ,  A61K9/146 ,  A61K9/1635 ,  A61K31/403 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/439 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/519 ,  A61K31/549 ,  A61K31/55 ,  A61K31/7068 ,  A61K31/708 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K2300/00

摘要： The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

公开(公告)号：EP2627651A1

公开(公告)日：2013-08-21

申请号：EP11773371.7

申请日：2011-10-12

申请人： Abbvie Inc.

发明人： DEGOEY, David A. ,  KATI, Warren M. ,  HUTCHINS, Charles W. ,  DONNER, Pamela L. ,  KRUEGER, Allan C. ,  RANDOLPH, John T. ,  MOTTER, Christopher E. ,  NELSON, Lissa T. ,  PATEL, Sachel V. ,  MATULENKO, Mark A. ,  KEDDY, Ryan G. ,  JINKERSON, Tammie K. ,  GAO, Yi ,  LIU, Dachun ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  MARING, Clarence J. ,  HUTCHINSON, Douglas K. ,  FLENTGE, Charles A. ,  WAGNER, Rolf ,  TUFANO, Michael D. ,  BETEBENNER, David A. ,  SARRIS, Kathy ,  WOLLER, Kevin R. ,  WAGAW, Sebel H. ,  CALIFANO, Jean C. ,  LI, Wenke ,  CASPI, Daniel D. ,  BELLIZZI, Mary E. ,  CARROLL, William A.

IPC分类号： C07D403/14

CPC分类号： A61K31/4184 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

摘要： Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

摘要翻译： 描述了有效抑制丙型肝炎病毒（HCV）复制的化合物。 本发明还涉及制备这些化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：EP3324941A1

公开(公告)日：2018-05-30

申请号：EP16745584.9

申请日：2016-07-18

申请人： AbbVie Inc.

发明人： ASMUS, Katharin ,  GAO, Yi ,  GARRETT, Colleen ,  HACH, Harald ,  JAYASANKAR, Adivaraha ,  KYEREMATENG, Samuel ,  LANDER, Ute ,  MUELLER, Thomas ,  NARIS, Marius ,  OBERMILLER, Constanze ,  REUL, Regina ,  SCHNEIDER, Katrin ,  SEVER, Nancy ,  SIIMON, Michael ,  STEITZ, Benedikt ,  TONG, Ping ,  WESTEDT, Ulrich ,  ZHU, Donghua

IPC分类号： A61K9/14 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K31/498 ,  A61P31/14

CPC分类号： A61K9/146 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/209 ,  A61K31/454 ,  A61K31/498

摘要： The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：EP2678334A1

公开(公告)日：2014-01-01

申请号：EP12716757.5

申请日：2012-02-24

申请人： Abbvie Inc.

发明人： DEGOEY, David A. ,  KATI, Warren M. ,  HUTCHINS, Charles W. ,  DONNER, Pamela L. ,  KRUEGER, Allan C. ,  RANDOLPH, John T. ,  PATEL, Sachin V. ,  MATULENKO, Mark A. ,  KEDDY, Ryan G. ,  JINKERSON, Tammie K. ,  LIU, Dachun ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  MARING, Clarence J. ,  HUTCHINSON, Douglas H. ,  FLENTGE, Charles A. ,  WAGNER, Rolf ,  BETEBENNER, David A. ,  SARRIS, Kathy ,  WOLLER, Kevin R. ,  CARROLL, William A. ,  GAO, Yi

IPC分类号： C07D403/14 ,  A61K31/4184 ,  A61K31/4164 ,  A61P31/14

CPC分类号： C07D403/14 ,  C07D207/16

摘要： Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.